Eric Rothman is counsel in the Corporate Department of Kaye Scholer’s New York office and a member of the firm’s Life Sciences Group.
Mr. Rothman represents a variety of domestic and foreign companies in a broad range of matters, with a particular focus on life sciences transactions. Mr. Rothman has represented many of the world’s most sophisticated life sciences companies, from early-stage biotechs to major international pharmaceutical companies, including businesses involved with drug development and manufacturing, biologics, biosimilars and other biotech products, generics and 505(b)(2) products, vaccines and diagnostics, and medical devices. Major clients include Novartis, Sandoz, Alcon, Pfizer, Celgene, Purdue Pharma and Mundipharma.
Mr. Rothman has experience structuring and negotiating transactions for both branded and generic products, including research collaborations and license agreements, university licenses and sponsored research agreements, option agreements, pre-clinical research agreements, material transfer agreements, licenses and co-development collaborations, clinical research agreements, contract research organization (CRO) agreements, co-promotion/co-development alliances, marketing and distribution agreements, product acquisitions and divestitures, manufacturing and supply agreements, transition service agreements, pharmacovigilance agreements, contract sales organization (CSO) agreements, and various other corporate partnering structures.
Mr. Rothman also counsels clients on contentious transactional matters, including complex settlements of commercial and intellectual property disputes involving life sciences technology.